Palbociclib for patients with hormone receptor positive / HER2-negative breast cancer that has recurred after surgical removal (POLAR) | SAKK

Palbociclib for patients with hormone receptor positive / HER2-negative breast cancer that has recurred after surgical removal (POLAR)

IBCSG 59-19 POLAR

Coordinating investigator

Stefan Paul Aebi

Prof. Dr. med.

Stefan Paul

Aebi

Luzerner Kantonsspital

+41 41 205 58 60

For further information on the IBCSG 59-19 POLAR trial, please consult the IBCSG website.

Clinics

All trials

More trials: Breast cancer

Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement

SAKK 23/16 TAXIS

Breast cancer: is surgery still necessary if tumor tissue can no longer be detected following chemotherapy?

SAKK 23/18 - VISION I

Researchers are looking for a better way to treat ER+/HER2- early-stage breast cancer

CAMBRIA-2

Triple-negative (hormone-independent) breast cancer, TNBC

SAKK 66/22